Abacavir, Lamivudine And Zidovudine Tablet
NDC Package 68180-286-07

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Abacavir, Lamivudine And Zidovudine tablets is classified as a

administered via oral route. This formulation utilizes a tablet delivery system. Marketed by Lupin Pharmaceuticals, Inc., this product is identified by NDC 68180-286 and is authorized under FDA application ANDA202912.

Identification & Billing

NDC Package Code
68180-286-07
Package Description
1 BOTTLE in 1 CARTON / 60 TABLET in 1 BOTTLE
Product Code
68180-286
11-Digit Billing Format
68180028607
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 307650 - abacavir sulfate 300 MG / lamiVUDine 150 MG / zidovudine 300 MG Oral Tablet
  • RxCUI: 307650 - abacavir 300 MG / lamivudine 150 MG / zidovudine 300 MG Oral Tablet
  • RxCUI: 307650 - abacavir (as abacavir sulfate) 300 MG / 3TC 150 MG / AZT 300 MG Oral Tablet
  • RxCUI: 307650 - abacavir 300 MG / 3TC 150 MG / AZT 300 MG Oral Tablet

Clinical Specifications

Proprietary Name
Abacavir, Lamivudine And Zidovudine
Non-Proprietary Name
Abacavir , Lamivudine And Zidovudine
Substance Name
Abacavir Sulfate; Lamivudine; Zidovudine
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class

Regulatory & Marketing

Labeler Name
Lupin Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA202912
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-17-2013
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68180-286-07 identifies a specific commercial package of 1 bottle in 1 carton / 60 tablet in 1 bottle of Abacavir, Lamivudine And Zidovudine, a human prescription drug labeled by Lupin Pharmaceuticals, Inc.. This tablet is formulated for oral use and contains abacavir sulfate; lamivudine; zidovudine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lupin Pharmaceuticals, Inc. on December 17, 2013. The current certification is valid through December 31, 2026.

How is this Lupin Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68180028607. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68180-286-07
11-Digit CMS (5-4-2)
68180-0286-07

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.